肥満 の ため の インクレチン: 銀 の 弾丸 より も ニコチン プラッシュ に 近い
Isabella Dippel1, Megan Adelman2, Kevin M Olson1
1USF Health Taneja College of Pharmacy, University of South Florida, Tampa, Florida, USA.
Expert opinion on pharmacotherapy
|September 3, 2025
まとめ
肥満の管理はインクレチンの薬物療法の使用の増加とともに進化しています. インクレチン療法と併せて行動支援を行うことで,体重減少と体重維持が促進され,健康状態が改善されます.
科学分野:
- 内分泌学と代謝
- 公衆衛生と疫学
- 行動医学
背景:
- 肥満は2型糖尿病や心臓病や 医療費の上昇に繋がる 世界的な流行病です
- 肥満に対するインクレチン薬物療法の処方量は急増しており,最新の臨床理解と管理戦略が必要です.
研究 の 目的:
- 行動介入とインクレチンの薬物療法に焦点を当てた 肥満管理に関する物語的なレビューを提供すること.
- インクレチン治療の効果と長期的体重管理の最適化に関する専門家の意見をまとめること.
主な方法:
- 多分野からなる専門家チームが 文献レビューを行った.
- 検討された主な分野は,行動介入,栄養,身体活動,体重減少のためのインクレチン薬物療法です.
主要な成果:
- インクレチン薬療法は,選択された患者で著しい体重減少につながる可能性があります.
- インクレチン治療の長期的遵守は様々であり,補完的な戦略の必要性を強調しています.
結論:
- インクレチン治療の効果を最大化するために,行動支援は極めて重要で,食事,運動,タンパク質の摂取を改善します.
- 統合された行動と薬学的アプローチは,肥満管理における持続的な体重減少と維持に不可欠です.
関連する概念動画
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
Regulation of Food Intake
350
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
350
Obesity
609
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
609
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255


